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Introduction
Oral anticoagulant therapy (OAT) is indicated for both pro-
phylactic and therapeutic use in patients with increased risk
of thromboembolism.1 The vitamin K antagonists (VKAs)
(e.g., warfarin) has been the main OAT for more than
60 years, but after approval of the direct oral anticoagulants
(DOACs; dabigatran etexilate, rivaroxaban, apixaban, and
edoxaban), the use of VKAs has been decreasing.2 However,
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Abstract Background Studies from several countries show that self-management of vitamin K
antagonist (e.g., warfarin) therapy reduce the risk of complications compared with
conventional management.
Objectives The aim of this study was to investigate the quality of warfarin manage-
ment when patients were transferred from conventional management to self-manage-
ment in Norway. In addition, quality of life (QoL) before and after 2 years of warfarin
self-management was investigated.
Materials and Methods The study was longitudinal with a retrospective and prospec-
tive design where 126 patients on conventional management of long-term warfarin
therapy underwent a 21-week training program of warfarin self-management followed
by 2 years of self-management. The outcomes of the study were time in therapeutic
range (TTR), the variance of international normalized ratio (INR) values, extreme INR
values (INR  1.5 and  5), complications, and QoL, comparing the 2-year period of
the conventional management with the 2-year period with the self-management.
Results The median TTR was higher during self-management compared with conven-
tional management (78.1% vs. 65.9%, respectively, p < 0.001). In addition, self-
management resulted in lower INR variance (0.22 vs. 0.33, p < 0.001), reduced
percentage of extreme INR values (1.8% vs. 5.3%, p < 0.001), less complications (0%
vs. 5.6%), and improved QoL (p < 0.001) compared with conventional management.
Conclusion Weused five differentmeasures and found improved quality of warfarin self-
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mechanical heart valve,3 with severely reduced renal func-
tion, and with antiphospholipid syndrome.4 Also, use of
DOACs in the elderly has been of concern because of comor-
bidity, drug–drug interactions, and decreased drug clear-
ance.5 In Norway, approximately 43,000 patients (1% of the
population) used warfarin and 115,500 patients (2% of the
population) used DOACs in 2018.6
Patient self-management (PSM) of VKA therapy is a
concept empowering the patients by enabling trained
patients to monitor and adjust their management in a
home setting. Meta-analysis from randomized clinical trials
show that PSM of VKA therapy reduces the risk for com-
plications compared with conventional management.7,8 A
cohort study from clinical practice in Denmark, with
5 years of follow-up, also found a reduction especially in
bleeding events, but also in thromboembolic events and
deaths in patients with mechanical heart valve performing
PSM compared with conventional management.9 In addi-
tion, a Cochrane review has demonstrated that quality of
life (QoL) during PSM increases compared with convention-
al management.8 Complications like thromboembolism,
bleeding, and death are decreased during VKA manage-
ment,1 and are used as primary outcomes in larger trials.
However, when the length of the study as well as the
number of patients are limited, time in therapeutic range
(TTR) is recommended as outcome for anticoagulant man-
agement.10 Meta-analysis show that TTR during PSM is
equal to or higher than that seen with conventional man-
agement.7,11 However, none of the studies included in the
meta-analysis have been performed in Norway. Since the
quality of conventional VKA management varies in different
countries,12 and methods used to train patients in self-
management may differ,13 it is important to compare PSM
with conventional management in each country. It must be
emphasized that PSM is an option only for a selected group
of patients.14 The estimates of suitability vary between 10
and 80% of the patients8,13 due to different criteria for
eligibility and indications for VKA management.15 In a
previous pilot study performed in Norway, a training pro-
gram for PSM of VKA therapy was tested, and was the first
study in Norway where results from PSM were compared
with conventional VKA therapy.16,17 For the 23 included
patients there were no difference in TTR when comparing
conventional management (39 weeks) with self-manage-
ment (23 weeks). In 2018, approximately 1,350 patients had
attended a revised version of this training program which
was originally developed at Aarhus University Hospital
(Denmark)18 and modified by the Norwegian Organization
of Quality Improvement of Laboratory Examinations
(Noklus).17 In Norway, the quality of the conventional
VKA management is relatively good (TTR: 70%),12 and
therefore of interest to explore, in a larger study, if PSM
could increase the quality even further. Thus, the aim of this
study was to investigate the quality of VKA therapy, using
four different outcomes, when patients are transferred from
conventional management to self-management in Norway.
In addition, we investigated the QoL before and after 2 years
with PSM of warfarin therapy.
Materials and Methods
Study Design
The study was longitudinal with a retrospective and pro-
spective design where the same patients constituted the
conventional and self-management group. All patients
started warfarin treatment in the conventional group, and
after the training in PSM, all patients were transferred to the
self-management group.
Study Population
Patients on long-term/life-long warfarin therapy were
recruited from December 2010 at general practitioners’
(GP) offices and cardiac outpatient clinics in Tromsø and
Bodø (Norway). A letter with information about the project
was sent to all GP offices (220), asking for patients that
could be suitable for the study. Also, the health care pro-
fessionals at the GP offices were informed about the project
so that they could inform eligible patients. Since there was a
low response from the GPs in Tromsø, there was an adver-
tisement in a local newspaper and at a Web page for GPs
collaborating with the Arctic University (University of
Tromsø) of Norway. In addition, the physician responsible
for the participants in Tromsø recruited patients from the
outpatient clinic at the University Hospital of North Norway.
The physician of each patient assessed her/his suitability for
warfarin self-management. This included physical health,
mental suitability, motivation, and expected level of compli-
ance with PSM. Patients had to be between 18 and 70 years
old. In addition, they had to have the ability and motivation
to follow the training program and take responsibility for
their own warfarin therapy. Exclusion criteria were drug
abuse and hepatic disease. The goal was to recruit approxi-
mately 150 patients which was the economic and practical
limit for the study. In addition, all the patients had to
complete the training program in self-management of war-
farin within 1 year. The GPs were in charge of warfarin
dosing during the conventional management period. All
participants gave written informed consent to participate
in the study. The study was approved by the Regional
Committee for Medical and Health Research Ethics, Western
Norway (REK/ 2008/4873), and the project is registered at
ClinicalTrials.gov (registration number NCT 02864537).
Study Intervention
All patients underwent a 21-week training program in self-
management of warfarin therapy between March 2011 and
February 2012 (►Table 1). The program follows international
guidelines14 and was originally developed at Aarhus Univer-
sity Hospital (Denmark)18 and modified and tested in a
Norwegian setting by Noklus.17 The content of the training
program has previously been described.17 In short, the first
period started with a 3-hour course where basic knowledge
of warfarin therapy and international normalized ratio (INR)
was the main focus, in addition to instructions and practice
in the use of the handheld point-of-care (POC) INR instru-
ment (CoaguChek XS [Roche Diagnostics, Switzerland]). For
2 weeks the participants themselves measured their INR
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every day with their own INR device, but assessment of dose
adjustment was performed only once a week based on
weekly INR values analyzed on the hospital instrument.
Decisions regarding warfarin doseweremade by the respon-
sible biomedical laboratory scientist (BLS) in consultation
with a physician. The second period started with a course
where the topicswerewarfarin dosing and fluctuation of INR
values. The participants measured their INR once a week for
7 weeks and suggested their warfarin dose followed by
approval/adjustment by the BLS/physician. In the third peri-
od, the participants decided the warfarin dose and the BLS/
physician checked every 4th week. After a total of 21 weeks,
the participants had to pass a written test to be allowed to
continue self-management (►Table 1). The written test is
theoretical/objective with questions regarding which prac-
tical aspects they must be aware of to perform a correct
measurement of INR with the POC instrument. Furthermore,
they are asked about how different food, medications, and
life-stylemay affect their INR values. In addition, they have to
answer how they will dose and when they will measure a
new INR in the case of a specific INR deviation from their own
therapeutic interval, and in the case they missed a warfarin
dose. During the training and self-management periods,
participants could contact the BLS by email or telephone
during the day if theywere hesitant about the INR analysis or
warfarin dosage or had other questions related to the man-
agement. They were instructed to contact the emergency
department or hospital in the event of symptoms/signs of
emergencies (e.g., bleeding or thrombotic complications).
The responsibility for the follow-up of the anticoagulation
therapy was transferred back to the GP after the training
period.
The INR Instrument Used
CoaguChek XS (Roche Diagnostics) is a small, handheld
device for the self-testing of INR. The device shows good
analytic performance19 with an analytical variation (CVa) of
approximately 3%20 and is easy for patients to use after thor-
ough training.20 Capillary blood from the finger is applied to a
test strip placed in the POC device for analysis of the INR. The
reagents SPA50/SPAþ (Stago, France) were used for analysis of
INR in citrated plasma on the hospital instruments, STA-R and
StaR Evolution (Stago). Standard procedures for internal and
external controls were followed, and gave acceptable results.
Results from the split-sample analysis (comparison of Coagu-
ChekXS INRresultwithhospital INRresult) showedthat theINR
values during the training period were within the acceptable
limits given by the International Organization for Standardiza-
tion for self-testing devices21 (►Supplementary Fig. S1, avail-
able in the online version).
Data Collection
The recommended therapeutic range and the INR values for
each patient 2 years before enrolment (conventionalmanage-
ment period), were obtained, as well as details of any compli-
cations experienced while on warfarin. These data were
obtained from the GP and/or the INR patient card. All INR
values, therapeutic range, and daily warfarin doses reported
during the training and self-management periods were
recorded, and patients were told to report any complications.
Data were collected from 2008 to 2013. At inclusion, each
participant filled out a validated QoL questionnaire developed
for patients on VKA.22 The questionnaire consists of 32 items
covering 5 management-related topics: general management
satisfaction, self-efficacy, distress, daily hassles, and strained
Table 1 Schematic overview of the training programa and self-management period
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Abbreviation: BLS, biomedical laboratory scientist; INR, international normalized ratio.
aModified from Hasenkam et al18 and Sølvik et al.17
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social network. A graded scale ranging from a minimum of 1
(Doesn’t apply) to maximum of 6 (Applies fully) is used. The
questionnaire was translated to Norwegian in the pilot study
and translated back to English to ensure that the translation
had not changed the meaning of the questions.16 The partic-
ipants filled in the same questionnaire after 2 years of self-
management.
Statistics
The outcome measures for the quality of warfarin treatment
were TTR, INR variance ( ), percentage of extreme INR
values (INR  1.5 and  5.0), and number of complications
(thromboembolic events and major hemorrhage). The calcu-
lations of the outcomes were performed using data from
2 years or the maximum length of conventional management
if this was less than 2 years (n ¼ 126). Likewise for the data
from the PSM period (n ¼ 126). In total, 92% of the patients
participated between 1.5 and 2 years both in the conventional
management and the PSM period (►Supplementary Table S1,
available in the online version). In addition, some variables
were calculated from 0.5, 1, 1.5, and 2 years before enrolment
(conventional management), during training in PSM, and after
0.5, 1, 1.5, and 2 years with PSM. The number of patients at
each of these time points is shown in ►Supplementary
Table S2 (available in the online version). Thromboembolic
events were defined as ischemic stroke or any form of throm-
boembolic events. Bleeding events were registered according
to the International Society on Thrombosis and Haemostasis
criteria.23 Major bleeding events were those that lead to
hospitalization, demanded blood transfusion, resulted in a
fall in hemoglobin level of  2.0 g/dL, were intracranial, or
resulted in death. Information about thromboembolic and
bleeding events in the conventional management period
were obtained from the patients’ GP. TTR, defined as the
number of patient days with INR values in the therapeutic
range divided by the total number of patient days, was calcu-
lated as described by Rosendaal and colleagues.24 In this
method, it is assumed that any given change in INR between
two measurements is linear. For each INR measurement, the
numberofdayswithin therapeutic range since the last testwas
calculatedanddividedby thenumberofdays since the last test.
Finally, the sum of total number of days within therapeutic
range was divided by the total number of days and multiplied
by 100. Analysis of QoL was performed as described by
Sawicki22 at baseline before training and after 2 years of
PSM. Baseline is defined as the point when the patients started
the training in self-management. The difference in TTR be-
tween the two periods (conventional management and PSM)
was normally distributed, and a paired t-test was used to test
for differences in TTR. TTR, INR variance, percentages of ex-
treme INR values, and QoL were not normally distributed, and
therefore the Wilcoxon signed-rank test was used to compare
these variables during conventional management and PSM,
andQoL at baseline and after2 yearswithPSM. Thedifferences
in all the parameters were calculated based on the same
number of patients in both the conventional and PSM groups
(TTR, INR variance, extreme INR values: n ¼ 126, QoL:
n ¼ 103). A Spearman’s correlation test was used to assess
if there was a correlation between INR variance and TTR,
between INR variance and the frequency of INR measure-
ments, between TTR and the frequency of INR measurements,
and betweenTTR andQoL. A p-value of  0.05was considered
to be statistically significant. Statistical analysis was per-
formed using Microsoft Excel version 15.39 and SPSS PASW
version 25 for Windows.
Results
In total,132patientswere recruited. Sixpatientswereexcluded
due to incomplete information about INR values from the
conventional management period (n ¼ 3), during training
(n ¼ 1), and/or during PSM (n ¼ 5). For the remaining 126
patients included in the calculations, the characteristics at
baseline are shown in ►Table 2. There were more men (69%)
than women, and the median age was 59 years (10th–90th
percentile 38–67). Therewas diversity in the therapeutic range
among thepatients,buteverypatienthad thesametherapeutic
range during the conventional management and PSM periods
Table 2 Patient characteristics at baseline
Number (N) 126
Gender
Female, n (%) 39 (31)
Male, n (%) 87 (69)
Age, median




Atrial fibrillation 33 (27)
Venous thromboembolism 32 (25)
Artificial heart valve 30 (24)
Arterial thromboembolism 18 (14)
Cannot be classifiedb 14 (11)
Duration of warfarin therapy
prior to study, median
(10, 90 percentiles), months
23.6 (7.2, 39.7)
INR target values
(therapeutic range), n (%)c
2.3 (2.0–2.5) 10 (7.9)
2.5 (2.0–3.0) 69 (55)
2.8 (2.5–3.0) 6 (4.8)
3.0 (2.5–3.5) 29 (23)
Otherd 12 (9.5)
Abbreviation: INR, international normalized ratio.
aFour patients had more than one indication for warfarin therapy.
bMissing: n ¼ 2 (1.6%), insufficient information to be classified: n ¼ 14
(11%).
cThe INR therapeutic range was decided by the general practitioners or
hospital physician.
dRange: 2.0–3.5, 2.2–3.3, 2.5–4.0, 2.5–4.2, 2.6–3.4, 2.6–4.4, 2.8–3.5,
3.0–4.0, 3.0–3.5.
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(►Table 2). The patients’ indications for warfarin therapy are
given in►Table 2. Sixty-two (49%) patients had usedwarfarin
for 2 years before enrolment, all 126 patients passed the
written test after 21 weeks of training in PSM and 77 (61%)
patients completed 2 years with PSM (►Supplementary
Table S2, available intheonlineversion). Themedianfrequency
of INR testing per month was higher during PSM compared
with conventional management (3.8 vs. 1.5 per month,
p < 0.001; ►Table 3).
Time in Therapeutic Range
The median value of TTR increased from 65.9 to 78.1% during
conventional management and PSM, respectively (p < 0.001;
►Table 3). Themean increase inTTRwas 8.3% (95% confidence
interval [CI]: 5.2–12, p < 0.001). There was no difference in
TTR between training in self-management and PSM (2.3, 95%
CI: –0.83, 5.4), and there was no difference between women
and men (data not shown). In total, 50% (n ¼ 63) of the
patients had an increase in TTR  10% from the conventional
management period to the PSM period, while 18% (n ¼ 23) of
the patients had a decrease in TTR  10% from the conven-
tionalmanagement period to the PSMperiod. Therewas a 50%
decreaseanda39% increase in thepercentagesofpatientswith
TTR < 40% and > 80%, respectively, from conventional man-
agement to PSM (►Fig. 1).
INR Variance, Extreme INR Values, and Complications
The median value of the INR variance decreased from 0.33
during conventional management to 0.22 during PSM
(p < 0.001; ►Table 3). The percentage of extreme INR values
(INR values  1.5 and  5.0) was lower during PSM compared
with conventional management (5.3% vs. 1.8%, p < 0.001;
►Table 3). There was an increase in TTR after 0.5 years with
PSM, thereafter a slight decrease and unchanged after 1 and
2 years (►Fig. 2A). INR variance was stable between training
and 0.5 year with PSM, but increased after 1 year compared
with training (►Fig. 2B). INR variance also increased after 1.5
and 2 years with PSM compared with training and 0.5 year
with self-management (►Fig. 2B). A negative correlation
between TTR and INR variance was found during conventional
Table 3 Observation time, frequency of INRmeasurements, time in therapeutic range, INR variance and extreme INR values during
conventional management and self-management
Conventional management Self-management p-Valuea
(n ¼ 126) (n ¼ 126)
Observation time,
median (10, 90 percentiles), months
23.6 (7.2, 24.8) 24.1 (13.4, 24.6) 0.081
Number of INR measurements per patient,
median (10, 90 percentiles)
30 (12, 50) 81 (37, 112)
Number of INR measurements per patient per month,
median (10, 90 percentiles)
1.5 (0.87, 2.6) 3.8 (2.0, 5.0) < 0.001
Time in therapeutic range,
median (10, 90 percentiles), %
65.9 (34.7, 92.3) 78.1 (43.8, 92.5) < 0.001
INR variance, median (10, 90 percentiles) 0.33 (0.16, 0.81) 0.22 (0.12, 0.56) < 0.001
Extreme INR values, % (n) 5.3 (207) 1.8 (173) < 0.001
INR values  1.5, % (n) 4.1 (160) 1.2 (120) < 0.001
INR values  5.0, % (n) 1.2 (47) 0.54 (53) 0.077
Abbreviation: INR, international normalized ratio.
aWilcoxon signed rank test.
Fig. 1 Percentage of the patients with time in therapeutic range (TTR) < 40%, 40–60%, 61–80%, and > 80% during conventional management
and self-management.
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managementandPSM(►Supplementary Table S3, available in
the online version). For conventional management and PSM, a
positive correlation was found between INR variance and the
frequency of INR measurements (►Supplementary Table S3,
available in the online version). For conventionalmanagement,
a negative correlation between the frequency of INRmeasure-
ments and TTR was found (►Supplementary Table S4, avail-
able in the online version). When excluding six patients with
high frequency of INRmeasurements (between 4.2 and 5.4 INR
measurements per month) and low TTR (between 33 and 57%)
in the conventional management period (►Supplementary
Table S5, available in the online version), there was no longer
a significant correlation between frequency of INR measure-
ments and TTR in the conventional management period.
Thromboembolic events andmajor hemorrhagewere reported
for 2.4 (n ¼ 3) and 3.2% (n ¼ 4) of the patients, respectively,
during the conventional management. No thromboembolic
events or major hemorrhage were reported during PSM.
Quality of Life
QoL improved after 2 years with PSM comparedwith baseline
(►Table 4). There was an increase in general management
satisfaction and self-efficacy (p < 0.001; ►Table 4). Daily
hassles, psychological distress, and a strained social network
decreased after 2 years with PSM compared with baseline
(p < 0.001; ►Table 4). There was no correlation between
TTR and QoL at baseline or after 2 years with PSM
(►Supplementary Table S6, available in the online version).
Discussion
In the present study, we found that the quality of warfarin
therapy in Norway improved when the patients were trans-
ferred from conventional management to self-management.
This is the first study that have used five different measures
for the quality of VKA, and there was an increase in TTR, a
A
B
Fig. 2 Median with 25th–75th percentiles error bars for (A) time in
therapeutic range (TTR) and (B) variance of international normalized
ratio (INR) during training (0.0 year) and at different time points
during self-management (0.5 year: n ¼ 123 [97%], 1 year: n ¼ 116
[91%], 1.5 years: n ¼ 108 [85%], 2 years: n ¼ 77 [61%]). p < 0.05
compared with training (0.0), p < 0.05 compared with training (0.0)
and 0.5 year with self-management (Wilcoxon signed-rank test).




Self-efficacy Distress Daily hassles Strained
social network
Baseline (before training)
Median (10, 90 percentile) 3.4 (1.9, 5.2) 5.0 (3.8, 5.8) 3.0 (1.6, 4.5) 2.3 (1.3, 3.4) 2.0 (1.0, 3.9)
Cronbach’s alpha 0.72 0.36 0.82 0.60 0.84
Self-management
Median (10, 90 percentile) 5.8 (4.4, 6.0) 5.8 (4.8, 6.0) 2.3 (1.1, 3.7) 1.6 (1.0, 3.0) 1.4 (1.0, 2.6)
Cronbach’s alpha 0.68 0.36 0.74 0.59 0.80
Difference self-management – baseline 2.00 0.57 –0.67b –0.53b –0.65b
p-Valuec < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Note: On a scale from 1 (doesn’t apply) to 6 (applies fully). Internal reliability is indicated by Cronbach's alpha. For general treatment satisfaction and
self-efficacy, improvement is indicated by an increase in scores. For distress, daily hassles, and strained social network, a decrease in the scores
indicate improvement.
aSix patients did not answer the QoL questionnaire before training and 24 patients did not answer the QoL questionnaire after self-management. Two
of these did not answer the QoL questionnaire either before or after.
bNegative values mean less distress, daily hassles, and strained social network.
cWilcoxon signed-rank test.
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decrease in INR variance, a decrease in extreme INR values
and complications, and an improvement in all the five
management-related QoL topics after 2 years with PSM of
warfarin therapy compared with 2 years with conventional
management.
TTR, INR variance, extreme INR values, and complications:
Several studies have shown that the risk of complications
increaseswith INR values outside the therapeutic range,10,25,26
and the deviation/variability of the INR measurements corre-
lates with the number of thromboembolic events, bleedings
events, and mortality.26,27 Thus, the two measures together
provide more information about risk for adverse events than
TTR alone28 as TTR reflects the achievement of appropriate
anticoagulation intensity regimenand INRvariabilitymeasures
stability of anticoagulation. TTR, INR variance, and extreme INR
values are therefore often used as surrogate measures for the
quality of VKA therapy. In the present study, fewer complica-
tions occurred during PSM compared with conventional man-
agement. However, due to the fact that only 126 patients
participated in this study, complications cannot be used as a
primary outcome.10 Furthermore, the risk of thromboembo-
lism and bleeding increase dramatically at INR below 1.5 and
above 5.0, respectively.29,30 Hence, the improvements in the
surrogatemeasuresduringPSMofVKAtherapymaypotentially
be extrapolated to a beneficial effect of this management
strategy on clinical outcome.
Our results are in line with previous studies from other
countries where TTR were similar31–36 or higher37–39 during
PSM compared with conventional management. However, a
direct comparison was difficult since the studies varies, for
example, how patients were selected, number of patients,
indications for VKA therapy, age, observation time, duration
of the training, and quality of the conventional management.
Thus,TTRduringconventionalmanagementhasbeenreported
to vary from 47% in Germany38 to 77% in the United King-
dom.31 In the previous pilot study performed inNorway, there
was no difference in TTR when the patients were transferred
from conventional management to PSM (TTR 70% vs. 75%,
respectively).17 However, in that study there were only 23
patients, and the follow-up time was only 28 weeks.
The number of patients with TTR > 80% increased from
25% during conventional treatment to 41% during PSM
(►Fig. 1), while a crossover study from the Netherlands
found that only 27% of the patients had TTR > 75% during
PSM versus 12% in the anticoagulation-clinic management
period.40 A 10% difference in TTR is defined as clinically
significant,41 and 50% of the patients in our study had an
increase in TTR of 10% or more when changing from conven-
tional management to PSM. Eighteen percent of the study
population (n ¼ 23) had a 10% or more decrease in TTR
during PSM. This is in line with the study from the
Netherlands reporting that 10 of 49 patients (20%) had better
control of anticoagulation in the anticoagulation-clinic
management than during PSM.40 In our study, 13 of these
23 patientsmainly had INRs above the therapeutic range, and
10 patients had INRs below the therapeutic range. It may be
speculated that these patients probably are not suitable for
self-management and should be transferred back to conven-
tional management or be offeredmore support also after the
training. To rapidly identify patients who experience worse
control when self-managing, the patients are recommended
to see their GP for a follow-up two to three times a year. In
addition, they are instructed to send their INR values to their
GP every 12th week and of course contact emergency
department or their GP, depending upon symptoms, if they
experience symptoms related to possible complications. In
case of an extreme INR value ( 5.0) andwhen opening a new
box with strips, they are instructed to contact their GP and
perform a parallel INR analysis at the GP office or at the
hospital. Patients with poor control have an individually
closer follow-up by the GP, and some are transferred to
only do self-measurement (i.e., they measure INR them-
selves, but the GP is contacted to do the warfarin dosing).
To optimize the scheme, a continuous revision based on
feedback from the patients is performed by Noklus. Further-
more, a plan for analytical quality control of the INR instru-
ments is under elaboration.
The decrease in thepercentagesof extreme INRvalues from
the conventional period to the PSM period (5.3% vs. 1.8%,
p < 0.001;►Table 3) in this study is in line with the previous
pilot study fromNorway (6.8%vs. 1.0%,p < 0.001).17However,
this is incontrast to thestudy fromtheNetherlandswherePSM
was compared with anticoagulation-clinic-management,
where no difference in extreme INR values was found (3.5%
vs. 5.3%).40
Wefoundamoderatenegative correlationbetweenTTRand
INR variance (conventional management: –0.36, PSM: –0.42;
►Supplementary Table S3, available in the online version).
These results are comparable with a previous cohort study
from Sweden with approximately 20,000 patients with atrial
fibrillation which also found a negative correlation (–0.27)
between the TTR and standard deviation of transformed INR
values.27 Furthermore, our results are similar to a cohort study
from the United States with approximately 40,000 patients
aged > 65 years where the negative correlation between the
TTR and log INR variability was –0.34.28 However, while TTR
was stable during 2 years with PSM, INR variance increased
after 1.5 and 2 years with PSM compared with training and
0.5 years with PSM (►Fig. 1). It must be emphasized that the
number of patients gradually decreased from 126 that com-
pleted the training in PSM to 77 (61%) that completed 2 years
with PSM (►Supplementary Table S2, available in the online
version). However,whenwe includedonly these 77patients in
the calculations, the same results for TTRwere obtainedwhile
INR variance increased only after 2 years with PSM compared
with training and0.5 yearswithPSM(datanot shown).Also, in
a study from Germany an increase in INR deviation was seen
between 6 and 12 months with PSM.22 In contrast, in a
randomized controlled trial from Austria with patients aged
 60 years, TTR increased from 70.6 to 75.4% at 6 and
12 months, respectively, with no change in INR variance.39
In that study, there was a follow-up visit every 6 months with
PSM. Also, in a cohort study from Denmark, a decrease in
event rates was observed from 1 year and after 5 years in
615 patients with mechanical heart valve performing PSM.9
Nevertheless, our results could indicate that despite the ability
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of patients to self-manage VKA therapy, some support may
be considered also after the training. In Norway, the responsi-
bility for the follow-up of the VKA therapy is transferred back
to the GP after training, while in Denmark the patients are
followed up by the anticoagulant clinic where the patients
were trained for self-management.42 Thus, a randomized
controlled trial showed that anticoagulation clinics provided
better VKA therapy than family physicians,43 possibly because
increased knowledge of VKA therapy seems to increase the
quality of treatment.44
Time within therapeutic INR target range is dependent on
the frequency of testing.45 Furthermore, studies have shown
that the variability in INR can be reduced by weekly INR
measurements.46 This may partly explain the increase in TTR
and decrease in INR variance during PSM compared with
conventional management as the number of measurements
increased from 1.5 to 3.8 per month (►Table 3). However, in
studies where the frequency of INR testing was similar during
PSMandconventionalmanagement thequalityofVKAtherapy
was comparable (INR testing about every 9 days)40 or better (a
smaller variance of INR; INR testing about once a month)46
during PSM. In addition, in trials comparing PSM and patients
who received training without performing self-monitoring
there were no difference in the quality in VKA therapy.36,47
Thus, increased knowledge contributes to improved compli-
ance and individualization which are factors that have shown
to improve the quality of anticoagulation.48 Hence, it appears
that the improvement is provided by the total concept of PSM
with training over time, increased knowledge, increase in the
frequency of testing, and focus. We cannot tell which of these
factors are of most importance. Furthermore, PSM offers the
opportunity tomeasure INRmore often, while this is often not
achievable in a busy GP practice.
Quality of Life
The improvement in QoL after 2 years with PSM confirms
the earlier pilot study from Norway16 and is in line with
previous studies using the same questionnaire in other
countries like the Netherlands,40 Germany,49 and Canada36
where the follow-up time was shorter (from 28 weeks to 6
months). QoL was not correlated with TTR at baseline or
after 2 years with PSM. This probably reflects that many
aspects of QoL are not affected by the quality of anticoagu-
lant treatment.
Number of Participants
Between 10 and 80% of patients using warfarin are estimated
to be suitable for PSM.8,13 The patients in this study were
recruited from approximately 220 GP offices, an outpatient
clinic at a hospital in addition to advertisement in a local
newspaper and at aWebpage. GPs inTromsø and Bodø have in
total approximately 1,200 to 1,500 patients each. However,we
do not have data on howmany eligible patients each GP office
had or howmany patientswere asked to participate. Thus, our
recruitment technique does not allow to calculate a “response
rate” of invited participants. Still, since approximately 1% of
the population in Norway use warfarin, the total number of
patients using warfarin available for recruitment in this study
was approximately 1,200 to 2,000. Thus, the 132 patients
recruited in this study constitute approximately 10% of this
population.
Strengths and Limitations
This is the first study that have used five outcome measures
(TTR, INR variance, extreme INR values, complications, and
QoL) for quality VKA therapy, and they were all in favor of
PSM. In addition, the observation period was longer for both
the conventional and PSM phase compared with previous
studies31,32,34–36,39,46 were the follow-up varied from 26
weeks32 to 12 months.34,39 Furthermore, the number of
patients was also higher compared with most of the earlier
studies.22,31,33,35–40,46 We do not have complete data for all
patients for 4 years. However, there were 62 patients during
2 years with conventional treatment and 77 patients during
2 years with PSM, which is more than most of the previous
studies.31,33,35–37,40,46 A “limitation” of our design could be
the lack of randomization and blinding. However, blinding is
not possible in this kind of study. The use of this design,
however, was a substantial strength of the trial as it was able
to control for differences between groups because the sub-
jects acted as their own control. The exclusion of patients
over 70 years of age may limit the generalizability of the
findings, but we assume that also patients older than
70 years who have the required physical and mental health,
are motivated and have the expected level of compliance
with PSM will be able to perform PSM. However, older
patients need more training time than younger patients.50
The training program with a duration of 21 weeks may
seem quite extensive compared with some of the previous
studies.22,32,34,37,39,40 However, the total duration (number
of hours) with lectures is comparable with other studies. In
our set-up, the patients gradually become self-managed, and
the accuracy of the POC INR instrument is monitored by
comparison with a laboratory instrument. About 1,200
patients have been trained in self-management by Noklus
using the same training program, demonstrating that this
training program also is feasible in a clinical setting. The
training program has been adapted from the program they
offer at Aarhus University Hospital in Denmark where more
than 1,500 patients have been trained. Due to the limited
number of training sessions, the trainers (physicians and BLS
or nurses) probably do not use more time on this program
compared with a shorter program with about the same
content.
Conclusion
In conclusion, we found that the quality of warfarin therapy
improvedwhen patients were transferred from conventional
management of warfarin therapy to PSM. This is the first
study using four different measures for the quality of VKA.
There was an increase in TTR, a decrease in INR variance, a
decrease in extreme INR values, and complications. In addi-
tion, there was an improvement in all the five management-
relatedQoL topics after 2 yearswith PSMof warfarin therapy
compared with baseline. To further improve the quality of
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VKA therapy, there should be an increased use of PSM for
eligible patients.
What is known about this topic?
• Several studies show that patient self-management
(PSM) of oral anticoagulant therapy with vitamin K
antagonists (VKAs) reduces the risk of complications
compared with conventional management.
• Studies have also shown that time in therapeutic range
(TTR) during PSM is equal to or higher than during
conventional management with improved quality of
life (QoL).
• There is limited knowledge about the quality of self-
management of warfarin therapy in Norway.
What does this paper add?
• This is the first study using five different outcome
measures (TTR, INR variance, extreme INR values,
complications, and QoL) for the quality of PSM of
warfarin therapy. An improvement was found in all
measures after 2 years when transferred from conven-
tional management in Norway.
• The improvement is probably provided by the total
concept of PSM with training over time, increased
knowledge, and focus, as well as the increased fre-
quency of INR testing.
• To further improve the quality of VKA therapy, there
should be an increased use of PSM for eligible patients.
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